Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study.

Department of Infectious Diseases, Luigi Sacco Hospital, via G.B. Grassi, 44, 20157 Milano, Italy.
Current HIV research (Impact Factor: 2.14). 02/2010; 8(2):165-71. DOI: 10.2174/157016210790442731
Source: PubMed

ABSTRACT HERMES is a prospective study, including all treatment-naïve patients attending scheduled visits at hospitals in the CISAI group in 2007. The present cross-sectional analysis aims to assess the baseline prevalence and characteristics of Metabolic Syndrome (MS) in a population of HIV-positive treatment-naïve patients. MS was diagnosed using the National Cholesterol Education Program (NCEP) definitions. A total of 292 subjects were enrolled, median age was 37 years, 75% of them were males. The prevalence of MS was 12.3%. The most frequent trio of abnormalities that led to the diagnosis of MS was high blood pressure, triglycerides and HDL. Univariate analysis showed that MS was associated with the following variables: age, education, physical activity, advanced HIV disease (CDC stage C or HIV-RNA >100,000 copies + CD4 <100 cells/mm(3)). Higher educational levels remained protectively associated with MS in multivariate analysis. A higher risk of MS was also associated with advanced HIV disease. Actually, treatment-naïve HIV-positive patients in an advanced stage of the disease have a higher prevalence of abnormal levels of triglycerides, HDL cholesterol and blood glucose than those at a less advanced stage. These findings of the HERMES study suggest, therefore, that HIV infection per se is associated to MS.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Cardiovascular (CV) risk is of increasing concern in HIV-infected individuals. The aim of the present study was to compare CV risk profile in HIV-infected patient in two Italian nationwide survey performed, 6 years apart. Design: Multicenter, case-control study. Methods: We analyzed CV risk in 765 Caucasian HIV-infected patients enrolled in 2005 (age 45.6±9 years, 74.0% men), and in 765 individually age- and sex-matched patients enrolled in 2011 (age 45.6±9 years, 74.0% men). Similar investigational procedures were followed in the two studies. Ten-year probability of major CV events and estimated vascular age were calculated using the Framingham Risk Score (FRS). Metabolic syndrome was diagnosed using new unified definition. The logarithm of molar ratio of triglyceridemia to high-density lipoprotein cholesterol was calculated as the atherogenic index of plasma (AIP). Results: Median FRS was 8.6% (interquartile range [IQR] 4.5-15.6) in 2005, vs 7.9% (3.9-15.6) in 2011 (p=0.04); vascular age was 51 (42-64) vs 48 (40-60) (p=0.02). Metabolic syndrome was present in 40.3 vs 33.4% (p=0.006). Blood glucose (5.36 ± 1.46 vs 5.03 ± 1.00 mmol/L), triglycerides (1.82 IQR 1.18-2.63 vs 1.52, IQR 1.05-2.19 mmol/L), prevalence of smokers (60.5% vs 49.9%) and lipodystrophy (43.5% vs 30.8%) were all significantly higher in 2005 (all p<0.0001). AIP was significantly more unfavorable in 2005 (p<0.0001). Median CD4 cells count was lower in 2005 (442, IQR 284-642 vs 581, IQR 429-770 cells/mm3, p<0.0001). Conclusions: Educational interventions and treatment decision making resorting in newer antiretrovirals may have contributed to significantly improve CV risk profile in new anti-HIV therapy era.
    AIDS 02/2014; 28(4). DOI:10.1097/QAD.0000000000000181 · 6.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to assess the prevalence of hypertension in an unselected human immunodeficiency virus (HIV)-infected population and to identify factors associated with hypertension prevalence, treatment, and control. We used a multicenter, cross-sectional, nationwide study that sampled 1,182 unselected, consecutive, HIV-infected patients. Office blood pressure was accurately measured with standard procedures. Patients were 71% men and 92% white, with a median age of 47 years (range = 18-78); 6% were antiretroviral treatment naive. The overall prevalence of hypertension was 29.3%; high-normal pressure accounted for an additional 12.3%. Among hypertensive subjects, 64.9% were aware of their hypertensive condition, 52.9% were treated, and 33.0% were controlled (blood pressure < 140/90mm Hg). Blood pressure-lowering medications were used in monotherapy in 54.3% of the subjects. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were the most frequently used drugs (76.1%: monotherapy = 39.1%, combination treatment = 37.0%). In multivariable regression models, hypertension was independently predicted by traditional risk factors, including age ≥50 years, male sex, family history of cardiovascular disease, body mass index ≥25kg/m(2), previous cardiovascular events, diabetes, central obesity, and metabolic syndrome, as well as by duration of HIV infection, duration of antiretroviral therapy, and nadir CD4(+) T-cell count <200/μl. The choice of protease inhibitors vs. nonnucleoside reverse transcriptase inhibitors as a third antiretroviral drug was irrelevant. Hypertension affects nearly 30% of HIV adult outpatients in Italy. More than one-third of the hypertensive subjects are unaware of their condition, and more than two-thirds are uncontrolled. A higher level of attention to the diagnosis and treatment of hypertension is mandatory in this setting.
    American Journal of Hypertension 09/2013; 27(2). DOI:10.1093/ajh/hpt182 · 3.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background: Human immunodeficiency virus (HIV) infection itself and highly active antiretroviral treatment (HAART) have been proposed to be associated with a higher prevalence of metabolic syndrome, but, to date, prevalence and phenotype of metabolic syndrome among HIV subjects and the related structural and functional vascular alterations are not conclusively defined. Methods: We analyzed the data of 108 HIV-infected subjects without known cardiovascular risk factors: 72 were on HAART (group A, age 46.5±7.5 years, clinical blood pressure 125.7/74.9±11.6/7.8 mmHg) and there 36 in a naïve group (group B, age 40.7±7.9 years, blood pressure 126/75.8±9.8/7.7 mmHg). A total of 224 healthy subjects served as controls (group C, age 44.9±6.9 years, blood pressure 123.7/75.7±9.8/7.1 mmHg). Arterial stiffness was measured by aorto-femoral pulse wave velocity (PWV, sfigmocor), and carotid intima media thickness (IMT) was measured by a semiautomatic echotracking system (Esaote-WTS). Results: Metabolic syndrome was more frequent in HIV-positive subjects than in controls (19.4%, 13.8%, 4.5% for groups A, B, and C; P<0.001), with no significant difference between HAART and naïve. In metabolic syndrome subjects, group A displayed lipid profile alterations more frequently (91%, 50%, 57% for groups A, B, and C; P<0.05), whereas others metabolic syndrome components were equally represented in the three groups. In metabolic syndrome subjects, IMT was similar [556±108, 542±164, and 564±110.4 μm for groups A, B, and C; P=not significant (NS)], whereas PWV was significantly greater in HAART subjects when compared with controls (10.8±1.8, 9.±1.1, 9.3±1 cm/sec for groups A, B, and C; P=0.02 for A vs. C). Moreover, in this group (metabolic syndrome+HAART), PWV was higher than in subjects on HAART but without metabolic syndrome. Conclusions: HIV subjects showed a higher prevalence and a different pattern of metabolic syndrome components. HAART, more than HIV infection per se, appeared to be responsible for the increased prevalence of metabolic syndrome and arterial function derangement.
    Metabolic syndrome and related disorders 07/2013; DOI:10.1089/met.2013.0008 · 1.92 Impact Factor